A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX?23 Six Months Later in Immunocompetent Adults Between 18 and 49 Y

Project: Other project

StatusActive
Effective start/end date7/1/186/30/20

Funding

  • Merck Sharp & Dohme Corporation: $16,392.58